ORIC Pharma reports $280.8M cash; pipeline milestones extend into 2023

Oric Pharmaceuticals, Inc.

Cash, cash equivalents and investments of $280.8M as of Dec 31, 2021; funds operations into first half of 2024.
ORIC-101 Phase 1b updates from two combination trials expected in first half of 2022.
Initial Phase 1b data for ORIC-533 (multiple myeloma), ORIC-114 (EGFR/HER2), and ORIC-944 (prostate cancer) expected in first half of 2023.
Two discovery programs advanced into lead optimization; new program/indication to be announced in 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.